Target
Platinum-doublet chemotherapy
4 abstracts
Abstract
Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP-OLIGO study (WJOG11118L): Feasibility analysis of induction therapy and local ablative therapy.Org: Radiation and Proton Therapy Center, Shizuoka Cancer Center, Division of Thoracic Surgery, Shizuoka Cancer Center, Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Department of Clinical Radiology, Graduate School of Medical Sciences, Department of Radiation Oncology, Juntendo University, Graduate School of Medicine,
Abstract
Final survival outcomes and exploratory biomarker analysis from the randomized, phase 2 neoSCORE trial: Two versus three cycles of neoadjuvant sintilimab plus chemotherapy for resectable non-small cell lung cancer.Org: The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China, Department of Thoracic Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, China, Department of Pathology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China, Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China,
Abstract
Clinicopathological features and treatment patterns of patients with cancer of unknown primary site (CUP): Mayo Clinic experience.Org: Mayo Clinic, Mayo Clinic, Department of Laboratory Medicine and Pathology, Mayo Clinic, Mankato,
Abstract
First-line immune checkpoint inhibitors alone or in combination with chemotherapy in real-life elderly patients with advanced non-small cell lung cancer (NEJ057).Org: Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tohoku University Graduate School of Medicine, Nippon Medical School Hospital, Niigata University Graduate School of Medical and Dental Sciences, Japanese Red Cross Okayama Hospital,